Product Inquiries Sample Clauses

Product Inquiries. In the event that any of the Impax Personnel, including, without limitation, any Impax PSR, receives any inquiries about any Detailed Product, Impax’s responsibilities shall be as follows: 6.6.1 For questions which Impax PSRs are unable to answer concerning Detailed Product identification, Detailed Product ingredients or stability/storage information, Impax and/or Impax’s Permitted Subcontractor(s) shall contact Wyeth Product Quality, at (▇▇▇) ▇▇▇-▇▇▇▇ or at ▇.▇. ▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇ (or such other person(s), address(es) and phone number(s) as Wyeth may designate from time to time by written notice to Impax). 6.6.2 For medical inquiries, including those related to information outside of labeling or which Impax PSRs are unable to answer, a form 8202 — Health Care Professional Request for Medical Information (a sample of which is attached hereto as Schedule 6.6) or equivalent (which equivalent is acceptable to Wyeth) (any such form, an “RPI Form”) must be completed (including the signature of the health care professional and such health care professional’s complete mailing address, telephone number and email address or fax number) and faxed to (▇▇▇) ▇▇▇-▇▇▇▇ or (▇▇▇) ▇▇▇-▇▇▇▇, or mailed to Wyeth Global Medical Communications, ▇.▇. ▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ (or such other address as Wyeth may designate from time to time by written notice to Impax). For emergency medical inquiries, call ▇▇▇-▇▇▇-▇▇▇▇ (or such other phone number as Wyeth may designate from time to time by written notice to Impax). Impax shall not, and shall cause the Impax PSRs to not, (i) solicit such medical inquiries and (ii) submit adverse event information on an RPI Form. 6.6.3 All responses to form 8202 inquiries from the medical profession or other Third Parties shall be given solely by Wyeth, Impax shall provide reasonable assistance to Wyeth to the extent deemed necessary by Wyeth to fully respond to such communications.

Product Inquiries. 5.1 Scotts will, at its sole cost, handle all product warranty and guarantee/satisfaction issues, response and compliance requirements, as well as all consumer inquiries, complaints, or reports of safety or quality issues (collectively “Consumer Inquiries”) relating to any of the FTO Cleared Products or FTO Review Products & Services. Scotts shall handle any such inquiries in a manner and process consistent with the handling of similar inquiries for its own products, using tools, by way of example, such as a toll-free consumer comments phone number and/or an e-mail or website address (as well as contact information for any other then customary method for such communications). Scotts will provide, and fund resources for staffing, such methods for receipt of consumer comments at least during normal business hours, and shall also provide and fund a referral provision for handling emergency calls/e-mails/communications outside normal business hours. Scotts agrees to log all consumer complaints, along with contact information, into a database for tracking purposes. Scotts shall submit to Monsanto to the below address a summarized report of complaints received thirty (30) days after the end of each calendar quarter, which will include the type of complaint received and geographic location of the complaints. With respect to consumer complaints that may reasonably be expected to cause harm to the Licensed Marks, Scotts shall expeditiously notify Monsanto of any such complaints and the Parties shall confer and cooperate as to how to handle or respond to such complaints. Any consumer contact information that is collected will be summarized in such a way to make it legally permissible that it be shared with Monsanto to the extent permitted by applicable Laws. Scotts will reasonably expeditiously notify Monsanto of information suggesting a verifiable safety issue with any of the FTO Cleared Products or FTO Review Products & Services. Subject to privilege considerations, Scotts shall provide Monsanto with significant, relevant data, including the results of any testing or investigations. Any notices to Monsanto pursuant to this Section shall be sent to the following address or such other addresses as Monsanto designates by written notice: Monsanto Company800 ▇. ▇▇▇▇▇▇▇▇▇ ▇▇▇▇.▇▇. Louis, MO 63167Attn: Deputy General Counsel 5.2 Scotts shall reasonably promptly notify Monsanto if Scotts obtains information that Scotts’ reasonably determines supports the conclusion that a...

Product Inquiries. Customer Service will provide information on product availability, song titles and artist information to the consumer. (i.e., Is this available ?, Who is this artist)

Product Inquiries. If Sanofi, or any Sanofi PSR, receives any inquiries about the Product, Sanofi’s responsibilities shall be as follows: (a) For questions that Sanofi PSRs are unable to answer concerning Product identification, Product availability or general inquiries, Sanofi shall contact the appropriate person and department designated in writing by Relypsa (or such other Person, at the address and phone number as Relypsa may designate from time to time by written notice to Sanofi). (b) For medical inquiries, including those related to information outside of labeling or which Sanofi PSRs are unable to answer, such medical inquiries shall go to Relypsa’s Medical Information Department.

Product Inquiries. If Allergan, or any Allergan PSR, receives any inquiries about the Product, Allergan's responsibilities will be as follows: 5.5.1 For questions that Allergan PSRs are unable to answer concerning Product identification, Product availability or general inquiries, Allergan will contact GSK Customer Service at ***, (or such other Person, at the address and phone number as GSK may designate from time to time by written notice to Allergan). 5.5.2 For medical inquiries, including those related to information outside of labeling or which Allergan PSRs are unable to answer, such medical inquiries will go to GSK's Medical Information Department.

Product Inquiries. If CV Therapeutics, or any CV Therapeutics PSR, receives any inquiries about the Product, CV Therapeutics’ responsibilities shall be as follows: (a) For questions that CV Therapeutics PSRs are unable to answer concerning Product identification, Product availability or general inquiries, CV Therapeutics shall contact Solvay Customer Service at ▇-▇▇▇-▇▇▇-▇▇▇▇, option 1 (or such other person, address and phone number as Solvay may designate from time to time by written notice to CV Therapeutics). (b) For medical inquiries, including those related to information outside of labeling or which CV Therapeutics PSRs are unable to answer, such medical inquiries shall go to CV Therapeutics’ Medical Information whenever the inquiries originate from CV Therapeutics PSRs. CV Therapeutics Personnel shall generate and provide prompt responses to such inquiries on CV Therapeutics letterhead, using Solvay’s standard responses where appropriate, and generating responses to unique requests where necessary. CV Therapeutics shall provide any such unique response to Solvay for comment via telecopy (under the notice provisions of Section 13.5 below) at least two (2) business days in advance. (c) Promptly after the Effective Date, Solvay shall provide CV Therapeutics with copies of all of Solvay’s standard responses to medical inquiries, so that CV Therapeutics may use such responses as provided in Section 7.5 above to respond to medical inquiries and to generate responses to unique requests for Solvay comment.

Product Inquiries. (a) For questions which Xcel sales representatives are unable to answer concerning Product identification, Product ingredients or stability/storage information, Xcel shall contact Elan, such contact information to be provided by Elan in writing. (b) For medical inquiries, including those related to information outside of labeling or which Xcel sales representatives are unable to answer, a form 8202 (Health Care Professional Request for Medical Information) must be completed and sent to Elan at the contact information to be provided by Elan in writing. Elan shall also provide in writing contact information for emergency medical inquiries. (c) All responses to form 8202 inquiries from patients, the medical profession or other third parties shall be given solely by Elan.

Product Inquiries. ViroPharma shall receive all Product inquiries including quality complaints, adverse drug reactions and requests for medical information. OSG shall notify ViroPharma within twenty-four (24) hours of any receipt of a Product inquiry and immediately forward it to ViroPharma. ViroPharma shall evaluate and, if necessary, request OSG’s support in its investigation.

Product Inquiries a. For questions which Co-Promotion Partner and its professional sales representatives are unable to answer concerning Product identification, Product ingredients or stability/storage information, Co-Promotion Partner shall refer such questions to Ligand's Professional Services Department. b. For medical inquiries, including those related to information outside of labeling received by Co-Promotion Partner and its professional sales representatives, Co-Promotion Partner shall refer such inquiries to Ligand's Medical Affairs Department. As between the parties, all responses to such inquiries from patients, medical professionals, or other third parties shall be provided solely by Ligand. Co-Promotion Partner shall provide reasonable assistance to Ligand, at Ligand's request and expense, in an effort to fully respond to such communications.